ϩ endothelial progenitor cells has the capacity to induce angiogenesis. In this study, we tried to induce angiogenesis by implanting expanded CD117
ϩ cells (P Ͻ 0.01) but not after the implantation of 2 ϫ 10 5 expanded CD117 ϩ cells (P Ͼ 0.05). These data indicate that ex vivo expansion of CD117 ϩ stem cells has low potency for inducing therapeutic angiogenesis, which might be related to the cellular senescence during ex vivo expansion.
ischemic; blood flow; senescence; differentiation VARIOUS METHODS OF INDUCING therapeutic angiogenesis have been successfully used in the treatment of several ischemic diseases (9, 20, 24) ; however, much recent attention has been focused on the use of cell-based therapy (1, 7, 12, 14, 16, 17, 21) . Unlike traditional methods of inducing therapeutic angiogenesis, cell-based therapy contributes not only to angiogenesis by producing multiple angiogenic growth factors from the implanted cells but also to vasculogenesis by the in situ differentiation of endothelial cells (ECs) from these implanted endothelial progenitor (stem) cells (18) .
Several stem cell sources, derived from peripheral blood, bone marrow, or embryonic stem cells, have been used to induce angiogenesis experimentally (1, 7, 11, 12, 14, 16, 17, 21) . Stem cells from peripheral blood or bone marrow are one of the most viable cell populations for clinical application because the implantation of autologous cells is not associated with problems of immunological rejection or ethical conflict. Some clinical trials have been done on implanting autologous
CD34
ϩ peripheral blood stem cells or bone marrow mononuclear cells to induce therapeutic angiogenesis for the treatment of ischemic heart or limb diseases (2, 5, 6, 8, 22, (25) (26) (27) (28) . The major problem associated with using autologous stem cells is limited supply because stem cells are a rare in peripheral blood and bone marrow.
Ex vivo expansion could resolve this problem. It was reported (13, 15) that the implantation of ex vivo expanded CD34 ϩ cells has the potential to induce therapeutic angiogenesis. Because there are more stem cells in bone marrow than in peripheral blood (3), we decided to separate stem cells from bone marrow for ex vivo expansion. Furthermore, we studied CD117 ϩ cells rather than CD34 ϩ cells because some of the CD34 Ϫ stem cells in bone marrow exhibit potential for proliferation and endothelial differentiation (10, 23) , and the CD117 ϩ cells in bone marrow play a key role in inducing angiogenesis (19) .
In this study, we expanded CD117 ϩ stem cells by culture supplemented with several cytokines and then injected these ex vivo expanded cells intramuscularly into the ischemic hindlimbs of mice. Unexpectedly, compared with freshly isolated CD117 ϩ cells, these expanded CD117 ϩ cells showed a very low potential for inducing therapeutic angiogenesis, which might be related with cellular senescence during ex vivo expansion.
METHODS

Animals.
Male 12-to 15-wk-old C57BL/6 mice were used for these experiments, which were approved by the Institutional Animal Care and Use Committee of Yamaguchi University. The animals were bred in clean conditions and allowed free access to food and water in a temperature-controlled environment with a 12:12-h light-dark cycle.
Separation and culture of CD117 ϩ cells. Bone marrow cells were collected from the femur and tibia, and mononuclear cells were isolated by density gradient centrifugation. CD117 ϩ cells were separated using a magnetic cell sorting system, as described previously (19) . Approximately 2.5% (1.6% to 3.2%) of the bone marrow cells expressed CD117, and the purity was ϳ90% by flow cytometry determination. These isolated CD117 ϩ cells have expressed ϳ99% of CD45, 30% of CD34, and Ͻ0.5% of vascular endothelial (VE)-cadherin.
Isolated CD117 ϩ cells were plated on culture dishes coated with 1% gelatin (Sigma) at a density of 2 ϫ 10 5 cells/ml in RPMI 1640 medium supplemented with 15% fetal bovine serum (GIBCO), 100 U/ml penicillin, and 100 g/ml streptomycin (GIBCO). Cells were incubated at 37°C in 5% CO 2. The following cytokines were added to the media: 50 ng/ml vascular endothelial growth factor, 5 ng/ml fibroblast growth factor, 5 ng/ml insulin-like growth factor-1, and 10 ng/ml stem cell factor. Additional feeding was performed every 3 days. After 3, 7, 14, 21, and 28 days of culture, CD117-derived adherent cells were harvested and the total number of surviving cells was counted. Because the proliferation of CD117 ϩ cells became poor after 14 days of culture, we collected expanded CD117 ϩ cells for the following study 14 days after cultivation.
For immunostaining analysis of endothelial differentiation, cells were seeded on 4-well chamber culture slides (Nalge Nunc International) coated with 1% gelatin and cultured as described above. After 14 days of culture, the cells were fixed in 1% formaldehyde and blocked with 2% BSA and then incubated with FITC-conjugated antibodies against CD34 (Pharmingen).
Flow cytometry. To characterize these ex vivo expanded CD117 ϩ cells, cells (10 5 ) were harvested after 14 days of culture and then incubated for 30 min at 4°C with the following antibodies: FITCconjugated monoclonal antibodies against CD34, VE-cadherin, and fetal liver kinase (Flk)-1 (Pharmingen), the FITC-conjugated CD3, CD14, and CD68 (Becton Dickinson). Isotype-identical antibodies served as controls. Quantitative flow cytometric analysis was done with the use of a FACScan flow cytometer and Cell Quest software (Becton Dickinson).
Senescence-associated ␤-galactosidase staining. After 7 and 14 days of culture, senescence-associated ␤-galactosidase staining was carried out as described previously (4) . The number of senescenceassociated (SA) ␤-galactosidase-positive cells was counted randomly under a microscope using ϫ200-fold magnification by a single observer and expressed as a percentage of all cells counted.
Ischemic hindlimb model and cell transplantation. The mouse ischemic hindlimb model was created as described previously (19) . Briefly, after the mice were given general anesthesia, the left femoral artery was exposed and ligated, and its branches were dissected free and excised. Thirty-six mice were divided randomly into three groups, and the quadriceps and adductor muscles of the ischemic hindlimb were injected at four points with: 2 ϫ 10 5 freshly isolated CD117 ϩ cells (Fresh group); 2 ϫ 10 5 expanded CD117 ϩ cells (Expanded group); or PBS injection only (PBS group). The induction of angiogenesis was estimated by histological analysis and blood flow assessment 2 wk after treatment.
To examine survival, endothelial differentiation, and the incorporation of cells after implantation, cells were labeled with intracellular fluorescent dye of 5(6)-carboxyfluorescein diacetate succinimidylester (CFSE) (Molecular Plobes) as described previously (19) and then injected into the ischemic hindlimbs of 20 supplementary mice divided into two groups as described above, excluding the PBS group.
Histological assessment. Histological analysis of microvessel density was done 2 wk after treatment, as described previously (19) . Briefly, five mice from each group were euthanized and the quadriceps and adductor muscles were harvested. Frozen sections of 5 m ϩ (data are representative of five independent experiments). C: quantitative analysis showed that the CD117 ϩ cells expanded by ϳ20-fold within 2 wk of cultivation but had poor proliferative potential thereafter. thickness were stained for alkaline phosphatase with an indoxyl tetrazolium method and then counterstained with eosin. The number of microvessels and muscle fibers were counted under a microscope using ϫ200-fold magnification by a single observer blind to the treatment regimen, and a total of 20 different fields on two independent slides from different cross sections were randomly selected for each mouse. The density of microvessels was estimated by the microvessel/muscle fiber ratio.
Five mice from each group were killed 7 and 14 days after the implantation of CFSE-labeled cells. Frozen sections were used to detect the survival of cells, and the microvessels were stained with R-phycoerythrin-conjugated anti-mouse CD34 antibody (Pharmingen) to examine cell survival, endothelial differentiation, and incorporation from the implanted cells.
Measurement of blood flow in the ischemic hindlimbs. Blood flow of the ischemic hindlimb was measured using the method of microsphere assessment as described previously (19) . Seven mice from each group were reanesthetized 2 wk after treatment, and 6 ϫ 10 4 /20 l of eosin Dye-Trak microspheres (15 m in diameter, Triton Technology) were injected into the abdominal aorta. The mice were euthanized 30 s later by severance of the abdominal aorta. Tissue specimens were collected from the hindlimbs and weighed and then digested in 2 M KOH containing 0.5% Tween 80, for 24 h at 60°C. The microspheres in the tissues were reclaimed, and dye from the microspheres was extracted with dimethyl formamide. The optical density (OD) of these dye samples was measured with a spectrophotometer. The recovery of perfusion in the ischemic hindlimb was estimated by comparing the percentage of limb blood flow (%LBF) with that in the normal right hindlimb, which was calculated as (OD of the ischemic limb/OD of the normal limb) ϫ (tissue weight of the normal limb/tissue weight of the ischemic limb) ϫ 100 (19) .
Data analysis. All data are presented as means Ϯ SD. Statistical significance was evaluated by ANOVA, followed by Scheffé's procedure and by repeated ANOVA to test for interactions. P Ͻ 0.05 was considered significant.
RESULTS
Characterization of ex vivo expanded CD117
ϩ cells. Many CD117 ϩ cells attached to the culture flask and showed a spindle-shaped morphology after 14 days of culture (Fig. 1A) . These cells also showed high expression of CD34 by immunostaining analysis (Fig. 1B) . Quantitative analysis showed that the CD117 ϩ cells expanded by ϳ20-fold within 2 wk of cultivation but that they had low proliferative potential thereafter, although several growth factors were supplied continuously (Fig. 1C) . Flow cytometry analysis also showed that these expanded CD117 ϩ cells have the qualitative properties of endothelial cells, with ϳ70% expression of several endothelial cell-specific antigens, including CD34 (70.2% Ϯ 6.9%), VEcadherin (66.7% Ϯ 7.5%), and Flk-1 (62.4% Ϯ 4.6%). Positive expression of CD3 (1.2% Ϯ 0.5%), CD14 (3.9% Ϯ 1.1%), and CD68 (1.8% Ϯ 0.6%) was seen in Ͻ5% of the cells (Fig. 2) . These results indicated that endothelial differentiation was induced during the culture of CD117 ϩ cells. Senescence of expanded cells. Senescence-associated ␤-galactosidase staining revealed SA ␤-galactosidase positivity in ϳ10% of the cells (11.4 Ϯ 4.8%) after 7 days of culture (Fig.  3A ) but in Ͼ70% (73.2 Ϯ 10.7%) after 14 days of culture (Fig.   Fig. 3 . Senescence of ex vivo expanded CD117 ϩ cells. About 12% of the cells showed positive staining for senescence-associated ␤-galactosidase activity after 7 days of culture (A), but Ͼ70% of the cells showed positive staining for senescence-associated ␤-galactosidase activity after 14 days of culture (B) (ϫ200 magnification). Survival and endothelial differentiation of cells after implantation. We examined survival of the CFSE-labeled CD117-derived cells in tissue sections from the ischemic hindlimbs. Microvessels were seen by immunostaining with R-phycoerythrin-conjugated antibody against mouse CD34, and colocalization confirmed the incorporation of implanted cells into microvessels. We found that many of the cells survived, showed endothelial differentiated, and were incorporated in microvessels 14 days after implantation, in the Fresh group (Fig. 4, A-C) . However, lower cell survival and incorporation were seen in the Expanded group (Fig. 4, D-F) .
Microvessel density in ischemic hindlimbs. After 2 wk of treatment, the microvessel/muscle fiber ratio, an index of neovascularization, was significantly higher in the Fresh group than in the PBS group (1.18 Ϯ 0.11 vs. 0.89 Ϯ 0.08, P Ͻ 0.01), but there was no significant difference between the Expanded and PBS groups (0.94 Ϯ 0.12 vs. 0.89 Ϯ 0.08, P Ͼ 0.05; Fig. 5 ).
Blood flow in ischemic hindlimbs after treatment. Blood flow of the ischemic hindlimb was estimated 2 wk after treatment. The LBF% was significantly higher in the Fresh group than in the PBS group (81.0 Ϯ 9.8% vs. 57.5 Ϯ 9.7%, P Ͻ 0.003) but not in the Expanded group (60.0 Ϯ 10.3% vs. 57.5 Ϯ 9.7%, P Ͼ 0.05; Fig. 6 ).
DISCUSSION
This study examined the capacity of ex vivo expanded bone marrow-derived CD117 ϩ stem cells to induce therapeutic angiogenesis. With the addition of several growth factors, these isolated CD117 ϩ cells expanded well, by Ͼ20-fold within 14 days, and showed high expression of several endothelial markers, indicating endothelial differentiation. Furthermore, the lack of expression of CD3, CD14, and CD68 cells indicated that there was no contamination of lymphocytes and macrophages although CD117 ϩ cells were well known generally as the population of hematopoietic stem cells. Although we achieved only ϳ20-fold expansion of CD117 ϩ cells, these ex vivo expanded cells showed similar characteristics and phenotypes to the expanded CD34 ϩ cells reported by Kalka et al. (13) . These findings suggest that the CD117 ϩ cell population includes endothelial precursors and can differentiate into endothelial cells in vitro.
Because we achieved only ϳ20-fold expansion of CD117 ϩ cells and found that the proliferation of CD117 ϩ cells was very low after 2 wk of culture, we measured endogenous cellular ␤-galactosidase activity, a marker of cellular senescence. More than 70% of cells were SA ␤-galactosidase positive after 14 days of culture, indicating that the majority of these CD117 ϩ stem cells had a senescent phenotype. Therefore, the proliferation of CD117 ϩ cells was poor after 2 wk of culture. However, immunostaining analysis by TdT-mediated DUTP nickend labeling method showed that the apoptotic index was Ͻ1% in the expanded CD117 ϩ cells after 2 wk of culture (data not shown). To examine the angiogenic potency by the implantation of ex vivo expanded cells, we injected 2 ϫ 10 5 of either 2-wk expanded CD117 ϩ cells or freshly collected CD117 ϩ cells into the ischemic hindlimbs of mice. The cell survival and incorporation of implanted cells were obviously poorer when expanded CD117 ϩ cells were used for implantation, rather than freshly collected CD117 ϩ cells. Furthermore, we found that these ex vivo expanded cells have a low potential for inducing therapeutic angiogenesis, based on the assessment of the microvessel density and the percentage of limb blood flow in the ischemic hindlimbs 2 wk after treatment.
In contrast to other reports (13, 15) , our results showed that the expanded CD117 ϩ cells had a low potential for inducing therapeutic angiogenesis, relative to freshly isolated CD117 ϩ cells, which could be attributed to the different cell source used for expansion or to the different culture conditions. However, we did not achieve satisfactory results even when we cultured the CD117 ϩ cells under the same conditions as described by Kalka et al. (13) .
Because the induction of therapeutic angiogenesis by cell therapy is related to both the production of angiogenic growth factors and the endothelial differentiation from implanted cells, several factors could compromise the angiogenic potential of expanded CD117
ϩ cells. The decrease in angiogenic growth factor production is considered to be an important factor, although our previous investigation indicated the contrary because a high concentration of vascular endothelial growth factor was measured in the CD117 ϩ cell suspension after 14 days of culture (19) .
It is well known that the ex vivo expansion of adult stem cells is very difficult. The senescence or phenotype changes of ex vivo expanded CD117 ϩ cells will result in decreased cell survival, endothelial differentiation, and incorporation after cell implantation, which is critically important for inducing angiogenesis. We speculate that the reason these expanded cells lost their potential for inducing angiogenesis was related to the senescence and the change of their phenotype, including the downregulation of membrane-bound receptors or adhesion molecules after ex vivo expansion. In fact, it was reported that ex vivo expanded CD34 ϩ cells have poorer engraftment potential than unexpanded cells (29) .
In summary, we found that the implantation of ex vivo expanded CD117 ϩ cells has low potential for inducing therapeutic angiogenesis, which could be related to the senescence of these expanded cells, and to poor survival and incorporation after implantation into the ischemic hindlimbs of mice. Further studies are needed to develop a new culture system of cell supply by ex vivo expansion for potential clinical cell-based therapy.
